The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in
gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of
information and technology, and by serving as a professional adviser to stakeholder communities
and regulatory bodies in Europe.

 

Icon
UPDATE
 

REGISTER HERE
Registration for ESGCT annual meeting in collaboration with DG-GT e.V.
!!! Abstract submission extended to July 14th !!!
More information on the programme and practicalities are availableon the Berlin page.

Latest News

Proof of concept for new strategy of genome editing to correct splice-site mutations

Read more

Step forward for precision medicine - personalised anti-cancer vaccine tested in patients

Read more

Genome editing used to treat Huntington's disease in mice

Read more

New developments in blood cell therapy

Read more

First clinical trial with in vivo genome editing

Read more

Phase I trial of gene therapy for age-related macular degeneration completed

Read more

ESGCT welcomes two Student Board Members

Read more

Feng Zhang Discusses CRISPR and Future of Gene Editing in Interview in Human Gene Therapy

Read more

New gene therapy success in a rare disease of the immune system: Wiskott-Aldrich syndrome

Read more

First stem-cell therapy recommended for approval in EU

Read more